Abstract:AF9 (MLLT3) and its paralog ENL(MLLT1) are members of the YEATS family of proteins with important role in transcriptional and epigenetic regulatory complexes. These proteins are two common MLL fusion partners in MLL‐rearranged leukemias. The oncofusion proteins MLL‐AF9/ENL recruit multiple binding partners, including the histone methyltransferase DOT1L, leading to aberrant transcriptional activation and enhancing the expression of a characteristic set of genes that drive leukemogenesis. The interaction between AF9 and DOT1L is mediated by an intrinsically disordered C‐terminal ANC1 homology domain (AHD) in AF9, which undergoes folding upon binding of DOT1L and other partner proteins. We have recently reported peptidomimetics that disrupt the recruitment of DOT1L by AF9 and ENL, providing a proof‐of‐concept for targeting AHD and assessing its druggability. Intrinsically disordered proteins, such as AF9 AHD, are difficult to study and characterize experimentally on a structural level. In this study, we present a successful protein engineering strategy to facilitate structural investigation of the intrinsically disordered AF9 AHD domain in complex with peptidomimetic inhibitors by using maltose binding protein (MBP) as a crystallization chaperone connected with linkers of varying flexibility and length. The strategic incorporation of disulfide bonds provided diffraction‐quality crystals of the two disulfide‐bridged MBP–AF9 AHD fusion proteins in complex with the peptidomimetics. These successfully determined first series of 2.1–2.6 Å crystal complex structures provide high‐resolution insights into the interactions between AHD and its inhibitors, shedding light on the role of AHD in recruiting various binding partner proteins. We show that the overall complex structures closely resemble the reported NMR structure of AF9 AHD/DOT1L with notable difference in the conformation of the β‐hairpin region, stabilized through conserved hydrogen bonds network. These first series of AF9 AHD/peptidomimetics complex structures are providing insights of the protein–inhibitor interactions and will facilitate further development of novel inhibitors targeting the AF9/ENL AHD domain.

Selective Targeting of AF9 YEATS Domain by Cyclopeptide Inhibitors with Preorganized Conformation.

Fragment-Based Discovery of AF9 YEATS Domain Inhibitors

Structure-guided Development of YEATS Domain Inhibitors by Targeting Π-Π-π Stacking

Structure-guided development of YEATS domain inhibitors by targeting pi-pi-pi stacking.

Discovering potential inhibitors of YEATS domain of YEATS2 through virtual screening, molecular optimization and molecular dynamics simulation

Structural insights into the π-π-π stacking mechanism and DNA-binding activity of the YEATS domain

Reading and erasing of histone crotonyllysine mimics by the AF9 YEATS domain and SIRT2 deacylase

Genetically Encoded Epitope Tag for Probing Lysine Acylation-Mediated Protein-Protein Interactions

Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain

Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia

Discovery of Selective Small-Molecule Inhibitors for the ENL YEATS Domain

YEATS Domain—A Histone Acylation Reader in Health and Disease

Exploring the Mechanism How AF9 Recognizes and Binds H3K9ac by Molecular Dynamics Simulations and Free Energy Calculations.

AF9 YEATS Domain Links Histone Acetylation to DOT1L-Mediated H3K79 Methylation

Structural studies of intrinsically disordered MLL‐fusion protein AF9 in complex with peptidomimetic inhibitors

Cyclic peptides target the aromatic cage of a PHD-finger reader domain to modulate epigenetic protein function

Leveraging a Phage-Encoded Noncanonical Amino Acid: A Novel Pathway to Potent and Selective Epigenetic Reader Protein Inhibitors

Targeting Yap/Taz-Tead Protein-Protein Interactions Using Fragment-Based And Computational Modeling Approaches

Selective Macrocyclic Inhibitors of DYRK1A/B.

Recognition of Histone Acetylation by the GAS41 YEATS Domain Promotes H2A.Z Deposition in Non-Small Cell Lung Cancer.

Targeting Yes-associated Protein with Evolved Peptide Aptamers to Disrupt TGF-β Signaling Pathway: Therapeutic Implication for Bone Tumor.